Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year.
The new drugs called panRAF inhibitors could be effective in patients with melanoma who have developed resistance to BRAF inhibitors.
The new study, jointly led by scientists at The Institute of Cancer Research, and the Cancer Research UK Manchester Institute, showed that the new drugs provisionally named CCT196969 and CCT241161 - stopped the growth of BRAF-driven melanomas, including those that had stopped responding to currently available BRAF-targeted drugs.
In addition, the new drugs halted tumour growth in cancers in which BRAF-targeted drugs had never worked in the first place - which happens in around 20 percent of cases.
The researchers showed that these new drugs work because they target both BRAF and the growth pathways that the cells come to rely on when they become resistant.
The studies established that for both drugs, a dose of 20mg per kg per day which when translated to humans would be achievable by taking in pill form caused tumours to regress without significant side-effects.
The study is published in the journal Cancer Cell.

Latest News from Lifestyle News Desk